IPO - BIO-PATH HOLDINGS, INC.

Form Type: 253G3

Filing Date: 2025-06-02

Corporate Action: Ipo

Type: New

Accession Number: 000110465925055486

Filing Summary: Bio-Path Holdings, Inc. is offering 35,714,285 shares of its common stock along with Series A warrants to purchase an equal number of shares at an offering price of $0.14 per share. This offering is conducted on a 'best-efforts' basis under Regulation A of the SEC, meaning no minimum number of securities must be sold for the offering to close. All proceeds will be available for use without any escrow, and investors may face risks including loss of their entire investment. The funds raised may reach up to $5,000,000, with a net yield to the company estimated at $4,650,000 after fees. Bio-Path Holdings is engaged in the development of RNAi nanoparticle drugs targeting cancer and obesity, using its proprietary DNAbilize® technology. The company has multiple drug candidates progressing through various phases of clinical trials. The offering circular outlines the risks associated with the investment and concludes by highlighting the importance of understanding investor suitability criteria. The offering is scheduled to commence following SEC qualification, with anticipated termination conditions outlined in the document.

Form Type: S-1/A

Filing Date: 2025-02-12

Corporate Action: Ipo

Type: Update

Accession Number: 000110465925011965

Filing Summary: Bio-Path Holdings, Inc. filed an amendment to its registration statement (Form S-1/A) on February 12, 2025, to register a public offering of up to 13,003,901 shares of common stock. This offering includes pre-funded warrants and common warrants, aimed at enabling investors to purchase shares while minimizing dilution. The offering is structured as a best-efforts sale with an assumed combined public offering price of $0.769 per share. The proceeds from this offering will be utilized to fund clinical trials for their drug candidates targeting several types of cancers, including acute myeloid leukemia (AML). The lead drug candidate, BP1001, is in a Phase 2 trial combining with decitabine and venetoclax. Additionally, the company highlights rigorous safety data from previous studies, projecting further advancement in clinical development and the exploration of expedited FDA programs. The Inclusion of various warrants in the offering relates to regulatory compliance concerning stockholder approvals, which will hinge upon specific pricing conditions being met under Nasdaq rules. The offer is also marked by operational risk factors and an acknowledgment of significant competition in the oncology sector that might impact enrollment in clinical trials.

Form Type: S-1

Filing Date: 2025-01-21

Corporate Action: Ipo

Type: New

Accession Number: 000110465925004576

Filing Summary: Bio-Path Holdings, Inc. filed a registration statement on Form S-1 with the Securities and Exchange Commission on January 17, 2025. The filing pertains to a public offering of shares of its common stock, along with pre-funded warrants and common warrants. The company aims to raise capital by offering its securities to institutional and accredited investors. This offering is described as a best-efforts public offering where the total number of shares and associated warrants is yet to be determined, contingent upon the market conditions and investor demand. The company’s common stock is listed on the Nasdaq Capital Market under the symbol 'BPTH'. The funds raised will be used to support the company’s clinical development and general corporate purposes. The document includes details concerning the potential exercise of warrants, pricing conditions, and risks associated with the offering, reflecting the company's emerging growth status.